The changes in weight, serum AST, ALT, glucose, total cholesterol

The changes in weight, serum AST, ALT, glucose, total cholesterol, and triglyceride

levels were evaluated. H&E and immunohistochemical (CD34, Caspase-3) analysis were performed on tissue samples. Quantitative real time PCR was performed to evaluate de novo lipogenesis markers (SREBP1c, FAS, and SCD-1), cholesterol synthesis marker (SREBP2), lipids uptake markers (PPAR-α, PPAR- γ), and inflammatory markers (TNF-α, MCP-1). Results: Compared to NAFLD both the liver (2.3±0.3 vs. 2.0 ±0.5, 1.9± 0.4, and 1.5± NVP-AUY922 datasheet 0.5 respectively) and liver to body weight ratio (0.049±0.004 vs. 0.044±0.01, 0.042±0.007, and 0.033±0.009 respectively) were significantly reduced in G1-G3 groups. Moreover, compared to the NAFLD, only G3 group showed significant reduction in serum ALT (88.0± 47.2 vs 32.3±10.3 mg/dl, p=0.013), total cholesterol (152.6±25.3 vs.121.9±35.0mg/ dl, p=0.015) and triglycerides (52.0± 11.8 vs. 30.1 ±12.1 mg/dl, p=0.033), respectively; however, G1 and G2 groups showed slightly deviations in results. The histological and immu-nohistochemical analysis showed decreased intrahepatic fat and caspase-3 activities (26.14±27.7 Ulixertinib price vs 12.2±17.8, p<0.01) in G3 group only. G1 and G2 groups showed statistically insignificant decrease in fat contents and caspase-3 activity. The decrease in CD34 activity in all GCS-F groups was also statistically

insignificant. All G-CSF groups showed decreased lipid de novo synthesis markers including SREBP1c, FAS, and SCD-1. Moreover, compared to NAFLD the TNF- α was also decreased in all G-CSF groups. However,

cholesterol synthesis marker and lipid uptake markers did not show significant results. Conclusions: G-CSF administration twice weekly for 4 weeks not only significantly decreased intrahepatic fat contents but also medchemexpress prevented apoptosis via decreased caspase-3 activity. Disclosures: Waqar K. Saeed – Grant/Research Support: Hanyang University Department of Internal Medicine Min Young Kim – Grant/Research Support: Hanyang University The following people have nothing to disclose: Ho Hyun Nam, Dae Won Jun, Sunmin Kim, Tae Yeob Kim, Joo Hyun Sohn, Eun Kyung Kim Nonalcoholic steatohepatitis (NASH) progression involves an initial inflammatory phase followed by a regenerative response that can lead to fibrosis. Molecular pathways of NASH are still evolving and there exists no proven treatment regimen in patients. Studies have shown that there is an activation of M1 macrophages in the NASH liver following several external or endogenous factors that can include inflammatory stimuli from adipose tissue, oxidative stress from altered fatty acid oxidation and cytokines. However, a direct role of oxidative stress in causing M1 polarization in NASH has been unclear.

Comments are closed.